share_log

Candel Therapeutics Analyst Ratings

Candel Therapeutics Analyst Ratings

取消 Therapeutics 分析師評級
Benzinga ·  2023/11/13 21:46
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/13/2023 1096.17% HC Wainwright & Co. → $11 Reiterates Buy → Buy
05/22/2023 1096.17% HC Wainwright & Co. → $11 Reiterates Buy → Buy
05/15/2023 226.23% BMO Capital $9 → $3 Maintains Outperform
03/31/2023 661.2% Credit Suisse $8 → $7 Maintains Outperform
12/07/2022 769.94% Credit Suisse $10 → $8 Maintains Outperform
12/02/2022 1096.17% HC Wainwright & Co. → $11 Initiates Coverage On → Buy
03/31/2022 1204.92% BMO Capital $18 → $12 Maintains Outperform
11/19/2021 1857.37% BMO Capital → $18 Initiates Coverage On → Outperform
08/23/2021 878.69% UBS → $9 Initiates Coverage On → Buy
08/23/2021 2292.34% Jefferies → $22 Initiates Coverage On → Buy
08/23/2021 1531.14% Credit Suisse → $15 Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目標價格變動 評級變動 之前/當前的評級
11/13/2023 1096.17% HC Wainwright & Co. → 11 美元 重申 購買 → 購買
05/22/2023 1096.17% HC Wainwright & Co. → 11 美元 重申 購買 → 購買
05/15/2023 226.23% BMO Capital 9 美元 → 3 美元 維護 跑贏大盤
03/31/2023 661.2% 瑞士信貸 8 美元 → 7 美元 維護 跑贏大盤
2022 年 7 月 12 日 769.94% 瑞士信貸 10 美元 → 8 美元 維護 跑贏大盤
12/02/2022 1096.17% HC Wainwright & Co. → 11 美元 啓動覆蓋範圍開啓 → 購買
03/31/2022 1204.92% BMO Capital 18 美元 → 12 美元 維護 跑贏大盤
11/19/2021 1857.37% BMO Capital → 18 美元 啓動覆蓋範圍開啓 → 跑贏大盤
08/23/2021 878.69% 瑞銀(UBS) → 9 美元 啓動覆蓋範圍開啓 → 購買
08/23/2021 2292.34% 傑富瑞集團 → 22 美元 啓動覆蓋範圍開啓 → 購買
08/23/2021 1531.14% 瑞士信貸 → 15 美元 啓動覆蓋範圍開啓 → 跑贏大盤

What is the target price for Candel Therapeutics (CADL)?

Candel Therapeutics(CADL)的目標價格是多少?

The latest price target for Candel Therapeutics (NASDAQ: CADL) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $11.00 expecting CADL to rise to within 12 months (a possible 1096.17% upside). 6 analyst firms have reported ratings in the last year.

HC Wainwright & Co. 於2023年11月13日公佈了Candel Therapeutics(納斯達克股票代碼:CADL)的最新目標股價。該分析公司將目標股價定爲11.00美元,預計CADL將在12個月內升至12個月內(可能上漲1096.17%)。去年有6家分析公司公佈了評級。

What is the most recent analyst rating for Candel Therapeutics (CADL)?

Candel Therapeutics(CADL)的最新分析師評級是多少?

The latest analyst rating for Candel Therapeutics (NASDAQ: CADL) was provided by HC Wainwright & Co., and Candel Therapeutics reiterated their buy rating.

HC Wainwright & Co. 提供了Candel Therapeutics(納斯達克股票代碼:CADL)的最新分析師評級,Candel Therapeutics重申了買入評級。

When is the next analyst rating going to be posted or updated for Candel Therapeutics (CADL)?

Candel Therapeutics(CADL)的下一次分析師評級何時公佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Candel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Candel Therapeutics was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Candel Therapeutics的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。Candel Therapeutics的最新評級是在2023年11月13日公佈的,因此您應該預計下一個評級將在2024年11月13日左右公佈。

Is the Analyst Rating Candel Therapeutics (CADL) correct?

分析師對Candel Therapeutics(CADL)的評級是否正確?

While ratings are subjective and will change, the latest Candel Therapeutics (CADL) rating was a reiterated with a price target of $0.00 to $11.00. The current price Candel Therapeutics (CADL) is trading at is $0.92, which is within the analyst's predicted range.

儘管評級是主觀的,並且會發生變化,但最新的Candel Therapeutics(CADL)評級得到了重申,目標股價爲0.00美元至11.00美元。Candel Therapeutics(CADL)目前的交易價格爲0.92美元,在分析師的預測區間內。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論